News - Biotechnology, Licensing

Filter

Current filters:

BiotechnologyLicensing

Popular Filters

126 to 150 of 374 results

ThromboGenics gains rights to DME drug

06-09-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Kyowa Hakko Kirin collaborates with Ultragenyx on KRN23

06-09-2013

Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into a collaboration and license…

BiotechnologyKRN23Kyowa Hakko KirinLicensingPharmaceuticalRare diseasesResearchUltragenyx

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

NovaBiotics enters co-development agreement for Novexatin

28-08-2013

Scotland-headquartered clinical-stage biotech firm NovaBiotics has entered into an exclusive agreement…

BiotechnologyDermatologicalsLicensingNovaBioticsNovexatinTaro Pharmaceuticals

Shire and Santaris extend strategic alliance

23-08-2013

Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says that its long term…

BiotechnologyLicensingPharmaceuticalRare diseasesResearchSantaris PharmaShire

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

Sirona Biochem signs LoI with leading Chinese diabetes company

22-08-2013

Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license…

Asia-PacificBiotechnologyDiabetesFosun PharmaLicensingPharmaceuticalSGLT2Sirona BiochemWanbang Pharma

Adimab enters collaborations with Celgene and Innovent; gets milestones

21-08-2013

USA-based therapeutic antibody developer Adimab this week announced two new collaborations, one with…

AdimabBiotechnologyCelgeneInnovent BiologicsLicensingResearch

MorphoSys closes on the alliance with Celgene

14-08-2013

German biotech firm MorphoSys (FSE: MOR) that its MOR202 alliance with Celgene (Nasdaq: CELG), the world's…

BiotechnologyCelgeneFinancialLicensingMOR202MorphoSysOncology

Amgen's US deal with Servier cleared

13-08-2013

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Novartis enters into a collaboration for Il-17 inhibitor

06-08-2013

US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Bionomics in $172 million pain treatment deal with US pharma giant

01-08-2013

Australian biotech firm Bionomics (ASX: BNO) has entered an agreement with US pharma giant Merck & Co…

BionomicsBiotechnologyLicensingMerck & CoNeurologicalPharmaceuticalResearch

Teijin and Amgen join forces on autoimmune disease research

31-07-2013

Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

AstraZeneca to fork out $815 million for rights to anemia drug candidate

31-07-2013

In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Array BioPharma signs up to $387 million deal

30-07-2013

In a second licensing deal this week US biotech major Celgene (Nasdaq: CELG) has entered into a strategic…

Array BioPharmaBiotechnologyCelgeneInflammatory diseasesLicensing

Acetylon snags $100 million upfront cash and acquisition option

30-07-2013

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Adocia re-acquires exclusive rights to insulin analog from US drug major

30-07-2013

French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Ligand enters global license deal for women's health product

23-07-2013

Ligand Pharmaceuticals (Nasdaq: LGND) announces the signing of a global license agreement with recently-formed…

Azure BiotechBiotechnologyGloballasofoxifeneLicensingLigand PharmaceuticalsPfizerPharmaceuticalWomen's Health

ADC Therapeutics and BZL Biologics sign antibody agreement

15-07-2013

Swiss ADC Therapeutics, a portfolio company of Auven Therapeutics, and USA-based BZL Biologics today…

ADC TherapeuticsAuven TherapeuticsBiotechnologyBZL BiologicsEuropeLicensingOncology

Italy's Chiesi gains rights to uniQure's Glybera

12-07-2013

Netherlands-based venture capital backed human gene therapy firm uniQure has signed collaboration agreements…

BiotechnologyChiesi FarmaceuticiGlyberaLicensingMergers & AcquisitionsPharmaceuticaluniQure

Start-up Loxo Oncology in deal with Array BioPharma

11-07-2013

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital in May this year,…

Array BioPharmaBiotechnologyLicensingLoxo OncologyOncology

Amgen gains rights to Servier's heart drugs ivabradine and S38844

10-07-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

Tengion closes deals to advance organ regeneration platform

09-07-2013

USA-based Tengion (OTCQB: TNGN), a leader in regenerative medicine, says it has now closed transactions…

BiotechnologyCelgeneFinancialLicensingResearchTengion

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

126 to 150 of 374 results

Back to top